ERBB2 and pancreatic adenocarcinoma: Five compounds have been tested and proven active in cultures of eight solid human tumors: Breast TNBC, Breast Luminal A, Breast Luminal B, Breast HER2 overexpressing, Melanoma, Pancreatic adenocarcinoma, NSCLC and Liver cancer.